Dr. Alpert is a surgical pathologist who focuses in gastrointestinal pathology. Her diagnostic expertise includes neoplastic and non-neoplastic diseases of the gastrointestinal tract, biliary tree, and pancreas.
University of Chicago
Chicago
Residency - Anatomic Pathology
2017
University of Chicago
Chicago
Fellowship - Gastrointestinal and Hepatic Pathology
2016
Columbia University College of Physicians and Surgeons
New York
MD
2012
Measuring the Submucosal Depth of Invasion in Endoscopic Mucosal Resections for Barrett-associated Adenocarcinoma.
Taylor AS, Setia N, Alpert L, Zhao L, Lamps LW, Hart J, Waxman I, Hissong E, Choi EK, Shi J, Owens S, Westerhoff M. Measuring the Submucosal Depth of Invasion in Endoscopic Mucosal Resections for Barrett-associated Adenocarcinoma. Arch Pathol Lab Med. 2022 Feb 25.
PMID: 35213893
Hypermucinous, Goblet Cell-Deficient and Crypt Cell Dysplasias in Inflammatory Bowel Disease are Often Associated with Flat/Invisible Endoscopic Appearance and Advanced Neoplasia on Follow-Up.
Choi WT, Salomao M, Zhao L, Alpert L, Setia N, Liao X, Drage MG, Westerhoff M, Cheng J, Lauwers GY, Ko HM. Hypermucinous, Goblet Cell-Deficient and Crypt Cell Dysplasias in Inflammatory Bowel Disease are Often Associated with Flat/Invisible Endoscopic Appearance and Advanced Neoplasia on Follow-Up. J Crohns Colitis. 2022 Jan 28; 16(1):98-108.
PMID: 34232295
Gastrointestinal stromal tumors (GISTs) arising in uncommon locations: clinicopathologic features and risk assessment of esophageal, colonic, and appendiceal GISTs.
Hu S, Alpert L, Cates JMM, Gonzalez RS. Gastrointestinal stromal tumors (GISTs) arising in uncommon locations: clinicopathologic features and risk assessment of esophageal, colonic, and appendiceal GISTs. Mod Pathol. 2022 Apr; 35(4):554-563.
PMID: 34702994
Dysphagia in Multiple Endocrine Neoplasia.
Kim GE, Alpert L, Siddiqui UD. Dysphagia in Multiple Endocrine Neoplasia. Gastroenterology. 2021 Oct 22.
PMID: 34688705
Adenomatoid tumours of the gastrointestinal tract?-?a case-series and review of the literature.
Hissong E, Graham RP, Wen KW, Alpert L, Shi J, Lamps LW. Adenomatoid tumours of the gastrointestinal tract?-?a case-series and review of the literature. Histopathology. 2022 Jan; 80(2):348-359.
PMID: 34480486
Hypermucinous, Goblet Cell Deficient, and Crypt Cell Dysplasias in Inflammatory Bowel Disease are Often Associated with Flat/Invisible Endoscopic Appearance and Advanced Neoplasia on Follow-Up.
Choi WT, Salomao M, Zhao L, Alpert L, Setia N, Liao X, Drage MG, Westerhoff M, Cheng J, Lauwers GY, Ko HM. Hypermucinous, Goblet Cell Deficient, and Crypt Cell Dysplasias in Inflammatory Bowel Disease are Often Associated with Flat/Invisible Endoscopic Appearance and Advanced Neoplasia on Follow-Up. J Crohns Colitis. 2021 Jul 07.
PMID: 34232295
A series of COVID-19 autopsies with clinical and pathologic comparisons to both seasonal and pandemic influenza.
McMullen P, Pytel P, Snyder A, Smith H, Vickery J, Brainer J, Guzy R, Wu D, Schoettler N, Adegunsoye A, Sperling A, Hart J, Alpert L, Chang A, Gurbuxani S, Krausz T, Husain AN, Mueller J. A series of COVID-19 autopsies with clinical and pathologic comparisons to both seasonal and pandemic influenza. J Pathol Clin Res. 2021 09; 7(5):459-470.
PMID: 33960723
Metastases can occur in cirrhotic livers with patent portal veins.
Mahdi Z, Ettel MG, Gonzalez RS, Hart J, Alpert L, Fang J, Liu N, Hammer ST, Panarelli N, Cheng J, Greenson JK, Swanson PE, Westerhoff M. Metastases can occur in cirrhotic livers with patent portal veins. Diagn Pathol. 2021 Feb 27; 16(1):18.
PMID: 33639984
Interobserver agreement and the impact of mentorship on the diagnosis of inflammatory bowel disease-associated dysplasia among subspecialist gastrointestinal pathologists.
Alpert L, Setia N, Ko HM, Lagana SM, Pittman ME, Johncilla M, Drage MG, Zhao L, Salomao MA, Liao X, Choi WT, Jenkins SM, Hart J, Harpaz N, Voltaggio L, Lauwers GY, Odze R, Remotti H, Smyrk TC, Graham RP. Interobserver agreement and the impact of mentorship on the diagnosis of inflammatory bowel disease-associated dysplasia among subspecialist gastrointestinal pathologists. Virchows Arch. 2021 Jun; 478(6):1061-1069.
PMID: 33392796
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.
Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth DK, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HL. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
PMID: 33234578